Intercept Pharmaceuticals, Inc.
ICPT · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $286 | $363 | $313 | $252 |
| % Growth | -21.4% | 16.2% | 24.1% | – |
| Cost of Goods Sold | $1 | $3 | $5 | $4 |
| Gross Profit | $285 | $360 | $307 | $248 |
| % Margin | 99.7% | 99.1% | 98.3% | 98.3% |
| R&D Expenses | $177 | $185 | $191 | $243 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $176 | $231 | $332 | $317 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $2 | $4 | $0 |
| Operating Expenses | $353 | $416 | $524 | $560 |
| Operating Income | -$68 | -$56 | -$217 | -$312 |
| % Margin | -23.9% | -15.3% | -69.3% | -124% |
| Other Income/Exp. Net | -$107 | -$36 | -$44 | -$32 |
| Pre-Tax Income | -$175 | -$91 | -$275 | -$345 |
| Tax Expense | -$290 | $54 | $49 | $46 |
| Net Income | $115 | -$145 | -$324 | -$391 |
| % Margin | 40.3% | -39.9% | -103.7% | -155.2% |
| EPS | 3.41 | -4.55 | -9.83 | -12.35 |
| % Growth | 174.9% | 53.7% | 20.4% | – |
| EPS Diluted | 3.4 | -4.55 | -9.83 | -12.35 |
| Weighted Avg Shares Out | 34 | 32 | 33 | 32 |
| Weighted Avg Shares Out Dil | 34 | 32 | 33 | 32 |
| Supplemental Information | – | – | – | – |
| Interest Income | $16 | $48 | $40 | $33 |
| Interest Expense | $21 | $54 | $48 | $41 |
| Depreciation & Amortization | $7 | $2 | $4 | $9 |
| EBITDA | -$62 | -$35 | -$212 | -$295 |
| % Margin | -21.6% | -9.6% | -67.9% | -116.9% |